Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) Income from Continuing Operations (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Income from Continuing Operations for 6 consecutive years, with 3747464.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 684.92% to 3747464.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 11059734.0, a 39.4% decrease, with the full-year FY2024 number at 8020578.0, up 27.56% from a year prior.
  • Income from Continuing Operations was 3747464.0 for Q3 2025 at Ensysce Biosciences, down from 1753674.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 640683.0 in Q3 2024 to a low of 16911455.0 in Q3 2021.
  • A 5-year average of 3831402.84 and a median of 2714963.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 2623.52% in 2021, then soared 123.6% in 2024.
  • Ensysce Biosciences' Income from Continuing Operations stood at 2104226.0 in 2021, then plummeted by 192.41% to 6153033.0 in 2022, then skyrocketed by 43.11% to 3500484.0 in 2023, then fell by 2.48% to 3587228.0 in 2024, then fell by 4.47% to 3747464.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Income from Continuing Operations are 3747464.0 (Q3 2025), 1753674.0 (Q2 2025), and 1971368.0 (Q1 2025).